MODAG Initiates First-in-Human Phase 1 Clinical Trial for anle138b (MODAG GmbH)
--Worldwide patent for anle138b secured --
WENDELSHEIM, Germany, December 18, 2019 – MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of, and recruitment for, a first-in-human Phase 1 study of lead candidate, anle138b in healthy volunteers.
MODAG Appoints Dr. Johannes Levin as Chief Medical Officer (MODAG GmbH)
WENDELSHEIM, Germany, September 4, 2019 – MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO).
MODAG Launches Out of Stealth Mode with Series A Financing of EUR 12 Million to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy (MODAG GmbH)
-- Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO --
-- SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio --
MODAG announced today the completion of a EUR 12 million Series A financing round, launching out of stealth mode to advance lead candidate anle138b into clinical development in Multiple System Atrophy (MSA).
New mouse model highlights promising potential drug for slowing Parkinson’s (Parkinson´s UK)
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Researchers at the University of Cambridge, funded by Parkinson's UK, have developed a new animal model and shown that anle138b may slow down the progression of Parkinson's by targeting toxic alpha synuclein-clumps.